Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow BDSX
Biodesix, Inc. (BDSX) EV/Sales
As of 16 October 2026, Biodesix, Inc. (BDSX) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from 0.5× (March 2022) to 7.5× (April 2021); the current reading is higher than 59% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | (69.10%) |
| FY2024 | 2.9× | (7.66%) |
| FY2023 | 3.2× | 76.90% |
| FY2022 | 1.8× | (20.21%) |
| FY2021 | 2.2× | 61.50% |
| FY2020 | 1.4× | (27.63%) |
| FY2019 | 1.9× | 0.00% |
| FY2018 | 1.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.4× | 44.44% |
| Mar 2026 | 1.7× | 85.71% |
| Dec 2025 | 0.9× | (17.03%) |
| Sep 2025 | 1.1× | 23.40% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MYGN Myriad Genetics, Inc. compare | 0.5× |
| FLGT Fulgent Genetics, Inc. compare | 1.0× |
| CSTL Castle Biosciences, Inc. compare | 2.0× |
| BDSX Biodesix, Inc. | 2.5× |
| XGN Exagen Inc. compare | 2.6× |
| QUCY Quantum Cyber N.V compare | 8.4× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 17.9× |
| MDXHF MedX Health Corp. compare | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. compare | 55.7× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)